

ASX Announcement

March 2022 Preclinical & Clinical Programs Update

31 March 2022 – Race Oncology Limited (“Race”) wishes to share an update on our clinical and preclinical programs, which were committed to in the Expected News in our December 2021 Quarterly Activity report (ASX Announcement: 28 January 2022). While the impact of COVID-19 has slowed some programs, we continue to make significant preclinical and clinical progress in Australia and internationally.

Preclinical: Cellular Programs

Race shared results of our preclinical kidney cancer program earlier this month (ASX Announcement: 10 March 2022). This study found Zantrene was able to kill a range of kidney cancer cells, both on its own and in combination with existing cancer treatments, and that when used in combination with the current kidney cancer treatment drugs lenvatinib, cabozantinib and pazopanib, greatly improved cell killing (synergy) was observed.

Race shared interim results of our collaborative extramedullary acute myeloid leukaemia (EMD AML) preclinical program in collaboration with Associate Professor Nikki Verrills (ASX Announcement: 17 March 2022). This program identified that Zantrene alone was able to kill a genetically diverse range of AML cells at low drug concentrations and that Zantrene in combination with decitabine showed significantly greater cell killing across a genetically diverse panel of AML cell lines and in mice than either drug on its own (synergy).

New cell-based studies exploring the potential of Zantrene in breast cancer, multiple myeloma, melanoma and kidney cancer, as well as further cardioprotection studies are underway with results expected in Q2 and Q3 CY 2022.

Preclinical: Animal Programs

Race shared the results of a mouse model study of AML EMD where Zantrene in combination with decitabine was found to target extramedullary AML tumours as well as kill AML cells present in the bone marrow and spleen (ASX Announcement: 17 March 2022).

Race is currently exploring Zantrene as a potential immunotherapeutic and treatment enhancer for existing oncology drugs in mouse models of melanoma.

The melanoma animal studies are nearing completion with results expected in early Q2 CY 2022. Results from these studies will be shared once the IP protection process is complete.

Animal studies exploring the cardioprotection potential of Zantrene against anthracycline and carfilzomib induced heart damage are underway. These studies are technically complex and time consuming with first results expected in Q2 CY 2022

New animal model studies in multiple myeloma and kidney cancer are in advanced planning and are expected to be initiated in Q2 CY 2022.

Clinical Programs

The Phase 1b/2 clinical trial of Zantrene in combination with fludarabine and clofarabine to treat relapsed/refractory (R/R) Acute Myeloid Leukaemia is progressing to expectation and is continuing to recruit patients. The study is being led by Professor Arnon Nagler of the Chaim Sheba Medical Center, Israel, who previously conducted the Phase 2 single agent Zantrene R/R AML trial, where a 40% clinical response was observed (ASX announcement: 16 June 2020). Race will update investors on progress upon completion of the Phase 1 dose-finding stage.

Progress on our Australian extramedullary AML-focused trial (RAC-006) is advancing with the support of the Contract Research Organisation (CRO), Parexel (ASX Announcement: 2 June 2021). While COVID-19 in New South Wales (Australia) has impeded this trial, Race expects to be able to update investors on human ethics and governance approval in early Q2 CY 2022.

Race announced (ASX announcement: 30 March 2022) that it has signed a clinical trial collaboration and supply agreement with Astex Pharmaceuticals, Inc (“Astex”), a subsidiary of Otsuka Pharmaceutical of Japan, to supply ASTX727 (oral decitabine and cedazuridine) for Race’s EMD AML & MDS trial RAC-006.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.

Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

In breakthrough preclinical research, Race has also discovered that Zantrene protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines and proteasome inhibitors to improve their ability to target breast cancer. Race is evaluating this discovery.

The Company also has compelling clinical data for Zantrene as a chemotherapeutic agent and is in clinical trial in Acute Myeloid Leukaemia (AML).



Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of Zantrene. Learn more at www.raceoncology.com

Release authorised by:

Phil Lynch, CEO/MD on behalf
of the Race Board of Directors
phillip.lynch@raceoncology.com

Media contact:

Jane Lowe
+61 411 117 774
jane.lowe@irdepartment.com.au